By Julie Steenhuysen CHICAGO, Nov 7 (Reuters) - An experimental Novartis drug designed to treat a genetic cause of heart ...
Novo Nordisk (NVO) has halted two late-stage trials of its experimental heart drug ziltivekimab, adding to the drugmaker’s recent pipeline setbacks. The Danish company said on Monday that an ...
Novo Nordisk A/S stopped two more trials for its experimental heart disease medicine, in a further blow to the drug’s prospects. Earlier this year Novo said ziltivekimab failed to reduce the risk of ...
On September 7, 2026, Reuters reported that Novo Nordisk A/S (NYSE:NVO) halted two additional trials of its experimental cardiovascular drug ziltivekimab, further denting the Danish drugmaker’s ...
Novo Nordisk halts two more ziltivekimab heart-failure trials after a data monitor found limited likelihood of success, leaving only the ARTEMIS post-MI study active. Novo Nordisk's STEP Young trial ...
Crow Wing, Wadena and Lake of the Woods counties will lose all Medicare Advantage plans in 2027, forcing rural seniors to compare more expensive alternatives before open enrollment ends Dec. 7.
Add Yahoo as a preferred source to see more of our stories on Google. The HERMES and ATHENA trials will stop due to a data monitoring committee's recommendation. Credit: Below the Sky / ...
Novo Nordisk is downgraded to Hold as GLP-1 franchise strength is offset by pipeline setbacks and growth normalization. Halting of ziltivekimab cardiovascular trials weakens Novo's diversification ...
Novo Nordisk has halted the HERMES and ATHENA late-stage trials of ziltivekimab after an independent data-monitoring committee determined they were unlikely to succeed. The decision follows the drug’s ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results